Dendritic Cell Maturation Stage Determines Susceptibility to the Proteasome Inhibitor Bortezomib
- 31 March 2007
- journal article
- research article
- Published by Elsevier in Human Immunology
- Vol. 68 (3), 147-155
- https://doi.org/10.1016/j.humimm.2006.12.005
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathwaysApoptosis, 2006
- Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicityBlood, 2005
- Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignanciesBlood, 2005
- Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosisBlood, 2005
- Phase II Trial of Bortezomib for Patients With Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2004
- Phase I Study of Bortezomib in Refractory or Relapsed Acute LeukemiasClinical Cancer Research, 2004
- Chemokine receptor CCR7 induces intracellular signaling that inhibits apoptosis of mature dendritic cellsBlood, 2004
- The Danger Model: A Renewed Sense of SelfScience, 2002
- NF-κB AND REL PROTEINS: Evolutionarily Conserved Mediators of Immune ResponsesAnnual Review of Immunology, 1998
- Function and Activation of NF-kappaB in the Immune SystemAnnual Review of Immunology, 1994